1. United States of America Stocks

  2. •

    Financial Services

  3. •

    Shell Companies
Myrexis, Inc.

Myrexis, Inc.

MYRX
Myrexis, Inc.US flagOther OTC
0.00
USD
- -
- -
27,583.00Market Cap
2008 Y
2009 Y
2010 Y
2011 Y
2012 Y
2013 Y
TTM
Revenue per Share
4.62
0.23
- -
0.01
- -
- -
- -
Basic EPS, GAAP
-1.43
-2.42
-1.91
-1.52
-1.18
- -
-0.42
Free Cash Flow per Basic Share
0.51
-2.84
-1.73
-1.31
-1.05
- -
-0.47
Dividend per Share
- -
- -
- -
- -
- -
- -
- -
Book Value per Share
- -
0.01
-1.9
-3.35
-4.42
- -
-4.6
Tangible Book Value per Share
-1.29
7.89
6.11
4.62
3.39
- -
0.04
Basic Weighted Avg Shares
24
24
25
26
26
- -
28
Sales/Revenue/Turnover
111
5
- -
- -
- -
- -
- -
Operating Margin (%)
-28.3
-1,065.54
-53,462.22
-21,864.86
- -
- -
- -
Depreciation Expense
3
3
1
2
1
- -
- -
Net Income, GAAP
-34
-58
-47
-39
-31
-12
-12
Effective Tax Rate (%)
- -
- -
- -
- -
- -
- -
- -
Profit Margin (%)
-31.03
-1,065.54
-52,167.78
-20,923.24
- -
- -
- -
Working Capital
-41
165
135
104
87
1
1
LT Debt
- -
- -
- -
- -
- -
- -
- -
Total Equity
-31
189
150
118
89
1
1
Return on Invested Capital (%)
- -
- -
- -
- -
- -
- -
- -
Return on Capital (%)
- -
- -
- -
- -
- -
- -
- -
Return on Common Equity (%)
- -
-48,446.67
- -
- -
- -
- -
- -

Capital Structure

FRC

•

in mil. unless spec.
Dec'13
Mar'13
Jun'13
ST Debt
- -
- -
- -
LT Borrowings
- -
- -
- -
LT Finance Leases
- -
- -
- -
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
27
34
34
Market Capitalization
76
3
2

Working Capital

FRC

•

in mil. unless spec.
Dec'13
Mar'13
Jun'13
Total Current Assets
83
2
1
Cash, Cash Equivalents & STI
81
2
1
Accounts Receivable, Net
- -
- -
- -
Inventories
- -
- -
- -
Total Current Liabilities
1
- -
- -
Payables & Accruals
1
- -
- -
ST Debt
- -
- -
- -
Deferred Revenue
- -
- -
- -

Growth Rates

FRC

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
- -
-175.7%
-98.7%
Free Cash Flow
- -
-157.57%
-53.29%
Net Income, GAAP
- -
-9.96%
-62.76%
Sales/Revenue/Turnover
- -
- -
- -
Total Cash Common Dividend
- -
- -
- -

Quarterly Revenue

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2011
- -
- -
- -
- -
- -
2012
- -
- -
- -
- -
- -
2013
- -
- -
- -
- -
- -

Quarterly Earnings Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2011
-0.4
-0.31
-0.5
- -
-1.52
2012
-0.33
-0.29
-0.4
- -
-1.18
2013
-0.13
-0.18
-0.11
- -
- -

Quarterly Dividends Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2011
- -
- -
- -
- -
- -
2012
- -
- -
- -
- -
- -
2013
- -
- -
- -
- -
- -

Company Description

APIChatGPT
CEO
Jonathan Couchman
Full Time Employees
1
Sector
Financial Services
Industry
Shell Companies
Address
630 Fifth Avenue New York City NY United States of America 10020
IPO Date
Jun 12, 2009
Website
myrexis.com
Similar Companies
BHAV Acquisition Corp Rights (BHAVR)
Lux Health Tech Acquisition Corp. (LUXA)
VPC Impact Acquisition Holdings (VIH)
Itiquira Acquisition Corp. (ITQ)
Ondo InsurTech Plc (ONDO.L)
Roth CH Acquisition III Co. (ROCR)
Business
Myrexis, Inc. Myrexis, Inc. (OTC: MYRX), a shell company headquartered in New York, New York, focuses on identifying, evaluating, and making financial investments in life sciences assets. Originally founded in 1999 as a spinoff from Myriad Genetics under the name Myriad Pharmaceuticals, Inc., the company renamed to Myrexis, Inc. in July 2010 and shifted from biopharmaceutical drug development in oncology and autoimmune diseases to its current investment mandate. It previously advanced cancer therapies including Azixa, MPC-3100, and MPC-9528; however, following clinical setbacks, it suspended all preclinical and clinical programs in February 2012, distributed assets to shareholders, and avoided liquidation to pursue strategic alternatives worldwide. Under CEO and CFO Jonathan Couchman, appointed in January and March 2013 respectively and operating via Couchman Management LLC, Myrexis maintains minimal operations with one employee and serves broker-dealer pricing needs in the OTC Pink market. The company planned liquidation in November 2012 subject to shareholder approval but continues as a dormant entity evaluating life sciences opportunities. No significant acquisitions, partnerships, funding rounds, or product launches have occurred since 2013, with recent activity limited to sustaining its shell status amid low trading volume.